Radiologist and surgeon. senior Assistant Chair of Radiology Jagiellonian University Collegium Medicum Kraków Poland. Interested in ultrasound - especially CEUS

Dr Valery Feigin is Professor of Neurology and Epidemiology and the Director of the National Institute for Stroke and Applied Neurosciences, Auckland University of Technology, New Zealand, and Affiliate Professor of the University of Washington, USA. He is also a Visiting Professor of the Capital Medical University of China, Honorary Professor of the Novosibirsk State Medical University, a Fellow of the Royal Society of New Zealand, American Academy of Neurology, and Russian Academy of Sciences. According to Web of Science, Valery Feigin is one of the 1% most cited scientists worldwide: just from the last year (2020) to 2021 his citation rate is one every 15 minutes (over 240,000 citations to date). Professor Feigin is Editor-in-Chief of the journal Neuroepidemiology (IF=5.4). He is also a co-Chair of the Global Policy Committee and Executive Committee member of the World Stroke Organization, Honorary Medical Director of Stroke Central New Zealand, and member of WHO Technical Advisory Group on NCD-related Research and Innovation.

Jens Fiehler is the Director of the Department of Diagnostic and Interventional Neuroradiology in the University Medical Center Hamburg-Eppendorf in Germany. He has published more than 600 peer-reviewed papers. As Associate Editor for the Journal of NeuroInterventional Surgery (JNIS) and Section Editor for Clinical Neuroradiology, he aims to support and foster high-quality neurointerventional research. His main research focus is the conception and execution of multi-center studies in cerebrovascular diseases that have been funded with several national and international grants. He is particularly interested in imaging analysis and advanced study methodology in neurointerventions. Jens Fiehler was a founding member of the European Society of Minimally Invasive Neurological Therapy (ESMINT) and is its past president.

Dr. Thalia Field is a stroke neurologist and clinician-researcher at the University of British Columbia where she is an Associate Professor and holds a Sauder Family/Heart and Stroke Professorship of Stroke Research, with a focus on clinical trials, neurocardiology and stroke in younger adults, particularly cerebral venous thrombosis. She is interested in stroke, vascular cognitive impairment and other post-stroke sequelae, particularly in high-functioning survivors, and engages in collaborative work with patients to best learn how to characterize these outcomes in research. She also investigates the impact of social determinants on brain health and has an outreach neurology clinic and has led knowledge translation initiatives through art outreach on Vancouver’s Downtown Eastside.

Prof. Urs Fischer is the Chairman of the Department of Neurology at the University Hospital Basel, Switzerland. Urs Fischer studied in Bern, London, San Francisco and Lomé and graduated in 2000. In 2008/2009, he performed a “Master of Science by Research in Clinical Neurology” at the University of Oxford. In 2015 he was elected as “Professor for Acute Neurology and Stroke” at the University of Bern. Since August 2021, he is chairing the Department of Neurology in Basel. Urs Fischer is a clinical researcher and his main research interest involves diagnosis, management, treatment and outcome of patients with acute neurological diseases, especially of patients with acute ischemic and hemorrhagic stroke. He is principal investigator of several international multicenter academic trials on the management of patients with ischaemic and haemorrhagic stroke. The SWIFT DIRECT trial (www.swift-direct.ch) has assessed whether adding intravenous thrombolysis to mechanical thrombectomy improves the patient outcome compared to direct mechanical thrombectomy alone (paper accepted for publication in The Lancet). The ELAN trial (www.elan-trial.ch) assesses when oral anticoagulation with direct oral anticoagulants in stroke patients with atrial fibrillation can be introduced. The SWITCH trial (www.switch-trial.ch) investigates whether decompressive craniectomy in addition to the best medical treatment is superior to best medical treatment alone for patients with intracerebral haemorrhage. The DISTAL trial aims to assess, whether mechanical thrombectomy in addition to best medical treatment in patients with distal, medium vessel occlusion (dMEVO, defined as an occlusion of the co- or non-dominant M2, M3 or M4, A2 or A3, P1, P2 or P3) is superior to best medical treatment alone. The TECNO trial aims to determine the safety and efficacy of intraarterial Tenecteplase in patients experiencing an acute ischemic stroke due to a large vessel occlusion with incomplete reperfusion with residual occlusions after mechanical thrombectomy. Urs Fischer is active in National and European Stroke Societies: he is the former Secretary General of the European Stroke Organisation (ESO), treasurer of the Swiss Neurological Society (SNG), member of the programme committee of the European Academy of Neurology (EAN), and he is co-founder the ESO ESMINT ESNR Stroke Winter School. Together with his colleagues of the stroke center Bern he is currently establishing the European Stroke Master Program, which started in 2022.

Biosketch- Marc Fisher, M.D. Dr. Fisher has had a long career as a translational and clinical researcher in the stroke field. He was at the University of Massachusetts Medical School for 36 years, retiring in 2014. While there, he led a stroke modeling lab for 25 years that focused on using MRI technology to evaluate the ischemic penumbra and the effects of many types of therapies on the evolution of ischemic injury. He trained more than 25 research fellows from around the world, many of whom currently hold prestigious positions. He participated in many clinical trials as a principal investigator or steering committee member. Dr. Fisher was also an active clinician and teacher. He has published more than 330 peer reviewed papers with an h-index of 80. Currently, Dr. Fisher is a part time member of the neurology faculty at Beth Israel Deaconess Medical Center in Boston and is a Professor of Neurology (part time) at Harvard Medical School. He continues to see patients and teach residents and stroke fellows. He was the Editor will -in-Chief of Stroke from 2010-2020 and continues to serve Stroke as a senior consulting editor. He assumed the presidency of the WSO in November 2020.

Neurologist and PhD in Neurology from the University of São Paulo, Associate Professor at the Federal University of Paraná. Fellow in Neurovascular and Neurosonology at the Sakler University of TelAviv, Israel. Titular Member of the Brazilian Academy of Neurology and Corresponding Member of the American Academy of Neurology. Representative Member of the Latin American Chapter of the Executive Committee on Neurosonology of the World Federation of Neurology.

Ana Catarina Fonseca is a neurology consultant and has a PhD in Medicine, from the Faculty of Medicine, University of Lisbon (2014). In 2014, she completed a Masters in Public Health from Harvard University (USA), having previously completed two masters: in Stroke Medicine at the University Danube Krems (Austria) and in Neuroscience at the University of Lisbon. She is a researcher at the Instituto de Medicina Molecular where she manages the stroke biobank collection, teaches Pharmacology and Neurology at the Faculty of Medicine (University of Lisbon) and works at the stroke unit of Hospital de Santa Maria in Lisbon, Portugal. She participated in the “value of treatment project” of the European Brain Council” and in the writing of guidelines for the “European Stroke Organization”. She is an editorial board member for Stroke, European Stroke Journal, International Journal of Stroke and BMC Neurology. Her main research interests are cryptogenic stroke, heart-brain interactions and precision medicine. https://orcid.org/0000-0001-6913-5526 https://twitter.com/CatarinaACF